- Reuters - UK Focus•27 days ago
A new leukaemia treatment from Novartis (IOB: 0QLR.IL - news) for children and young adults will get priority review from the U.S. Food and Drug Administration (FDA), putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. The FDA's announcement late Wednesday means the regulator plans to take action within six months on Novartis's so-called chimeric antigen receptor T cell therapy, or CAR (HKSE: 0699-OL.HK - news) -T, in partnership with University of Pennsylvania researchers.
- Fool.co.uk•last month
Here are two potential growth shares that might not be so obvious.
- Business Wire•10 months ago
NEWPORT BEACH, Calif.--(BUSINESSWIRE)-- Event to Feature One-on-One Meetings Between Institutional Investors and Senior Management Teams Representing Companies Focused on the Biotechnology, Medical Technologies ...
OXB.L: Summary for OXFORD BIOMEDICA PLC ORD 1P - Yahoo Finance
Oxford BioMedica PLC (OXB.L)
LSE - LSE Delayed price. Currency in GBp
Add to watchlist
|Bid||4.28 x 2513500|
|Ask||6.00 x 11600000|
|Day's range||4.56 - 4.79|
|52-week range||2.98 - 6.25|
|PE ratio (TTM)||-782.50|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|